1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Drugs In Development, 2022, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 8, 1, 45 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Uveitis - Overview
- Uveitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Uveitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Uveitis - Companies Involved in Therapeutics Development
- Uveitis - Drug Profiles
- Uveitis - Dormant Projects
- Uveitis - Discontinued Products
- Uveitis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Uveitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Uveitis - Dormant Projects, 2022
- Uveitis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Uveitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABIONYX Pharma SA
- Acelyrin Inc
- Aciont Inc
- Active Biotech AB
- Aerie Pharmaceuticals Inc
- Akari Therapeutics Plc
- Aldeyra Therapeutics Inc
- Alpine Immune Sciences Inc
- Alvotech ehf
- Amytrx Therapeutics Inc
- Avirmax Inc
- BioMarck Pharmaceuticals Ltd
- BioNanoSim Ltd
- Bonac Corp
- Cellivery Therapeutics Inc
- Celltrion Inc
- Chugai Pharmaceutical Co Ltd
- Dobecure SL
- E&B Technologies LLC
- Elasmogen Ltd
- Enzo Biochem Inc
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- HanAll Biopharma Co Ltd
- IACTA Pharmaceuticals Inc
- iCELL Biotechnology Co Ltd
- Inovio Pharmaceuticals Inc
- Juvenescence UK Ltd
- Kiora Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kriya Therapeutics Inc
- Kubota Vision Inc
- MeiraGTx Holdings Plc
- Mitotech SA
- Naegis Pharmaceuticals Inc
- NeuClone Pty Ltd
- Novaliq GmbH
- Novartis AG
- Oculis SA
- OKYO Pharma Ltd
- OncoNOx ApS
- ONL Therapeutics Inc
- Orchid Pharma Ltd
- OSE Immunotherapeutics SA
- Oxular Ltd
- Palatin Technologies Inc
- Panag Pharma Inc
- Parvus Therapeutics Inc
- Pharmapraxis
- Reven Holdings Inc
- Revolo Biotherapeutics Ltd
- RiniSight Inc
- Ripple therapeutics Corp
- SFA Therapeutics Inc
- Shanghai Henlius Biotech Inc
- Shennong Biotech Inc
- Skye Bioscience Inc
- Sol-Gel Technologies Ltd
- Tarsius Pharma Ltd
- Tianjin Pharmaceuticals Group Co Ltd
- Topas Therapeutics GmbH
- Valitor Inc
- Vyome Therapeutics Inc
- Worg Pharmaceuticals Hangzhou Co Ltd
- Wuhan Healthgen Biotechnology Corp
